Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of conjunctivitis
3.2.1.2 Technological advancements
3.2.1.3 Easy availability and increased awareness levels
3.2.2 Industry pitfalls & challenges
3.2.2.1 Associated adverse effect of drugs and patent expiration
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Antibiotic
5.3 Antiviral
5.4 Anti-allergic
5.5 Artificial tear
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Disease Class, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Bacterial conjuctivitis
6.3 Viral conjuctivitis
6.4 Allergic conjuctivitis
6.4.1 Seasonal allergic conjunctivitis
6.4.2 Perennial allergic conjunctivitis
6.4.3 Other allergic conjunctivitis
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Topical
7.3 Oral
Chapter 8 Market Estimates and Forecast, By Formulation Type, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Tablets and capsules
8.3 Ointment
8.4 Drops
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Online pharmacies
9.4 Retail pharmacies & drug stores
9.5 Other distribution channels
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 AFT Pharmaceuticals
11.3 Ajanta Pharma Limited
11.4 Alembic Pharmaceuticals
11.5 Bausch & Lomb Incorporated
11.6 Cipla, Inc.
11.7 JAWA Pharmaceuticals Pvt. Ltd.
11.8 Novartis AG
11.9 NicOx SA
11.10 Ocular Therapeutics, Inc.
11.11 Santen Pharmaceuticals Co. Ltd.
11.12 Sun Pharmaceuticals Industries Ltd.
11.13 Spectra Vision Care Pvt. Ltd.
11.14 Teva Pharmaceutical Industries Ltd.
